Directly Measured Insulin Resistance and the Assessment of Clustered Cardiovascular Risks in Hypertension

American Journal of Hypertension

Volumn 19, Issue 11, 2006, Pages 1118-1124

  Lin, Ming Wei ^b   Hwu, Chii Min ^a,b   Huang, Yung Hsiang ^c   Sheu, Wayne H H ^d   Shih, Kuang Chung ^e   Chiang, Fu Tien ^f   Olshen, Richard ^g   Chen, Yii Der I ^h   Curb, J David ⁱ   Rodriguez, Beatriz ⁱ   Ho, Low Tone ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Factor analysis; hypertension; insulin sensitivity; obesity

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FACTORIAL ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEADY STATE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; ASIAN AMERICANS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CARDIOVASCULAR PHYSIOLOGY; COHORT STUDIES; FACTOR ANALYSIS, STATISTICAL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; RISK ASSESSMENT; RISK FACTORS;

EID: 33750332992     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.04.003     Document Type: Article

References (31)

1. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., Norgiolini S., Bracco C., and Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
2. DeFronzo R.A., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
3. Scheen A.J., Paquot N., Castillo M.J., and Lefèbvre P.J. How to measure insulin action in vivo. Diabetes Metab Rev 10 (1994) 151-188
4. Lind L., Berne C., and Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 13 (1995) 1457-1462
5. Gray R.S., Fabsitz R.R., Cowan L.D., Lee E.T., Howard B.V., and Savage P.J. Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 148 (1998) 869-878
6. Ferrannini E., Haffner S.M., Mitchell B.D., and Stern M.P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34 (1991) 416-422
7. Miranda P.J., DeFronzo R.A., Califf R.M., and Guyton J.R. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 149 (2005) 33-45
8. Hanley A.J.G., Festa A., D'Agostino Jr. R.B., Wagenknecht L.E., Savage P.J., Tracy R.P., Saad M.F., and Haffner S.M. Metabolic and inflammation variable clusters and prediction of type 2 diabetes. Factor analysis using directly measured insulin sensitivity. Diabetes 53 (2004) 1773-1781
9. Donahue R.P., Bean J.A., Donahue R.D., Goldberg R.B., and Prineas R.J. Does insulin resistance unite the separate components of the insulin resistance syndrome?. Evidence from the Miami Community Health Study. Arterioscler Thromb Vasc Biol 17 (1997) 2413-2417
10. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88 (2003) 2399-2403
11. Ranade K., Hsuing A.C., Wu K.D., Chang M.S., Chen Y.T., Hebert J., Chen Y.-D.I., Olshen R., Curb D., Dzau V., Botstein D., Cox D., and Risch N. Lack of evidence for an association between α-adducin and blood pressure regulation in Asian populations. Am J Hypertens 13 (2000) 704-709
12. Hwu C.M., Hsiao C.F., Sheu W.H.H., Pei D., Tai T.Y., Quertermous T., Rodriguez B., Pratt R., Chen Y.-D.I., and Ho L.T. Sagittal abdominal diameter is associated with insulin sensitivity in Chinese hypertensive patients and their siblings. J Hum Hypertens 17 (2003) 193-198
13. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., and National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. J Am Med Assoc 289 (2003) 2560-2572
14. Pan W.H., Flegal K.M., Chang H.Y., Yeh W.T., Yeh C.J., and Lee W.C. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr 79 (2004) 31-39
15. Hwu C.M., Kwok C.F., Chiang S.C., Wang P.Y., Hsiao L.C., Lee S.H., Lin S.H., and Ho L.T. A comparison of insulin suppression tests performed with somatostatin and octreotide with particular reference to tolerability. Diabetes Res Clin Pract 51 (2001) 187-193
16. Wu K.D., Hsiao C.F., Ho L.T., Sheu W.H.H., Pei D., Chuang L.M., Curb D., Chen Y.-D.I., Tsai H.J., Dzau V.J., Cox D., and Tai T.Y. Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance Sibling Study. Hypertens Res 25 (2002) 529-536
17. Anderson P.J., Critchley J.A.J.H., Chan J.C.N., Cockram C.S., Lee Z.S.K., Thomas G.N., and Tomlinson B. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 25 (2001) 1782-1788
18. Meigs J.B. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all?. Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 152 (2000) 908-911
19. Lempiäinen P., Mykkänen L., Pyörälä K., laakso M., and Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly non-diabetic men. Circulation 100 (1999) 123-128
20. Edwards K.L., Burchfiel C.M., Sharp D.S., Curb J.D., Rodriguez B.L., Fujimoto W.Y., LaCroix A.Z., Vitiello M.V., and Austin M.A. Factors of the insulin resistance syndrome in nondiabetic and diabetic elderly Japanese-American men. Am J Epidemiol 147 (1998) 441-447
21. Leyva F., Godsland I.F., Ghatei M., Proudler A.J., Aldis S., Walton C., Bloom S., and Stevenson J.C. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18 (1998) 928-933
22. Hanley A.J.G., Karter A.J., Festa A., D'Agostino Jr. R., Wagenknecht L.E., Savage P., Tracy R.P., Saad M.F., and Haffner S. Factor analysis of metabolic syndrome using directly measured insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 2642-2647
23. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., Charles M.A., and Bennett P.H. A two-step model for development of non-insulin-dependent diabetes. Am J Med 90 (1991) 229-235
24. Morales P.A., Mitchell B.D., Valdez R.A., Hazuda H.P., Stern M.P., and Haffner S.M. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes 42 (1993) 154-161
25. Catalano M., Aronica A., Carzaniga G., Seregni R., and Libretti A. Serum lipids and apolipoproteins inpatients with essential hypertension. Atherosclerosis 87 (1991) 17-22
26. Gaziano J.M., Sesso H.D., Breslow J.L., Hennekens C.H., and Buring J.E. Relation between systemic hypertension and blood lipids on the risk of myocardial infarction. Am J Cardiol 84 (1999) 768-773
27. Selby J.V., Newman B., Quiroga J., Christian J.C., Austin M.A., and Fabsitz R.R. Concordance for dyslipidemic hypertension in male twins. J Am Med Assoc 265 (1991) 2079-2084
28. Frost P.H., Davis B.R., Burlando A.J., Curb D., Guthrie Jr. G.P., Isaacsohn J.L., Wassertheil-Smoller S., Wilson A.C., Stamler J., and Systolic Hypertension in the Elderly Research Group. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 94 (1996) 2381-2388
29. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., and ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trail. Lancet 361 (2003) 1149-1158
30. Bestermann W., Houston M.C., Basile J., Egan B., Ferrario C.M., Lackland D., Hawkins R.G., Reed J., Rogers P., Wise D., and Moore M.A. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 329 (2005) 292-305
31. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304